AMENDMENT NO. 1 TO THE LICENSE AGREEMENTLicense Agreement • April 15th, 2025 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances)
Contract Type FiledApril 15th, 2025 Company IndustryThis Amendment No. 1 to the License Agreement (this “Amendment”), dated January 17, 2024 (the “Amendment Effective Date”), is made by and between Windtree Therapeutics, Inc., a Delaware corporation formerly known as Discovery Laboratories, Inc. (“Windtree”), and Philip Morris Products S.A., a Switzerland corporation (“PMPSA”). Windtree and PMPSA are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO THE LICENSE AGREEMENTLicense Agreement • April 16th, 2024 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances)
Contract Type FiledApril 16th, 2024 Company IndustryThis Amendment No. 1 to the License Agreement (this “Amendment”), dated January 17, 2024 (the “Amendment Effective Date”), is made by and between Windtree Therapeutics, Inc., a Delaware corporation formerly known as Discovery Laboratories, Inc. (“Windtree”), and Philip Morris Products S.A., a Switzerland corporation (“PMPSA”). Windtree and PMPSA are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.”